Key result
The electrospun matrix composed of polycaprolactone, human serum albumin, and 3% dimethyl sulfoxide released a maximum of 80% of sirolimus over 27 days in blood plasma, enabling prolonged delivery.
Why the study?
Although drug-eluting coatings for vascular stents are in commercial use, more efficient stent coatings and drug delivery systems are needed.
Absolute Event Rate: 80% vs 100%
Electrospun polycaprolactone-based matrices containing human serum albumin and DMSO provide prolonged release of sirolimus, suggesting potential utility for vascular stent coatings.
Merits testing in vascular stent models; leaves open translation to clinical safety and efficacy.
Although a number of drug-eluting coatings for vascular stents (VSs) have been developed and are in commercial use, more efficient stent coatings and drug delivery systems are needed. Sirolimus (SRL) is a clinically important drug with antiproliferative and immunosuppressive activities that is widely used for coating stents. Here, we characterized SRL-enriched matrices, intended for coating vascular stents, that were produced by electrospinning (ES) on a drum collector from a solution of polycaprolactone (PCL) and human serum albumin (HSA), 1,1,1,3,3,3-hexafluoroisopropanol (HFIP), dimethyl sulfoxide (DMSO), and SRL. The release of tritium-labeled SRL (3H-SRL) from matrices in phosphate-buffered saline (PBS) or human blood plasma (BP) was studied. The introduction of DMSO in the ES blend decreased SRL release. The use of BP significantly accelerated SRL release through binding with serum biomolecules. The exchange of PBS or BP after every time point also increased SRL release. The maximum SRL release in BP was observed at 3 days. The matrices produced from the ES solution with DMSO and HSA released no more than 80% SRL after 27 days in BP, even under medium exchange conditions. Therefore, PCL-based matrices containing HSA, SRL, and DMSO can be used for coating VSs with prolonged SRL delivery.
No takes yet. Share an insight, caveat, or question.
Nazarkina et al. (2020) studied Vascular stent coating (In vitro). Sirolimus-eluting electrospun matrices (PCL/HSA/DMSO) vs. Matrices without DMSO was evaluated on Sirolimus release in blood plasma over 27 days. The electrospun matrix composed of polycaprolactone, human serum albumin, and 3% dimethyl sulfoxide released a maximum of 80% of sirolimus over 27 days in blood plasma, enabling prolonged delivery.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: